Expression of two major isoforms of MYO7A in the retina: Considerations for gene therapy of Usher syndrome type 1B

Vision Res. 2023 Aug 14;212:108311. doi: 10.1016/j.visres.2023.108311. Online ahead of print.ABSTRACTUsher syndrome type 1B (USH1B) is a deaf-blindness disorder, caused by mutations in the MYO7A gene, which encodes the heavy chain of an unconventional actin-based motor protein. Here, we examined the two retinal isoforms of MYO7A, IF1 and IF2. We compared 3D models of the two isoforms and noted that the 38-amino acid region that is present in IF1 but absent from IF2 affects the C lobe of the FERM1 domain and the opening of a cleft in this potentially important protein binding domain. Expression of each of the two isoforms of human MYO7A and pig and mouse Myo7a was detected in the RPE and neural retina. Quantification by qPCR showed that the expression of IF2 was typically ∼ 7-fold greater than that of IF1. We discuss the implications of these findings for any USH1B gene therapy strategy. Given the current incomplete knowledge of the functions of each isoform, both isoforms should be considered for targeting both the RPE and the neural retina in gene augmentation therapies.PMID:37586294 | DOI:10.1016/j.visres.2023.108311

Source: Vision Research - August 16, 2023 Category: Opthalmology Authors: W Blake Gilmore Nan W Hultgren Abhishek Chadha Sonia B Barocio Joyce Zhang Oksana Kutsyr Miguel Flores-Bellver M Valeria Canto-Soler David S Williams Source Type: research